Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data

This article was originally published in The Tan Sheet

Executive Summary

Adverse event reports related to ephedrine alkaloid dietary supplement use almost doubled between 1997 and 1999, according to poison control center data cited in a Sept. 5 citizen petition to FDA.

You may also be interested in...



Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman

There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1

Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman

There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1

Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman

There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel